New Trial: Aura Air’s Efficacy Against Influenza A
With seasonal flu being a major burden on the public's health and productivity, new test results offer a promising solution against the virus that causes the epidemic with 99.998% effectiveness.
Aura Air has released new test results from a trial held by Innovative Bioanalysis Laboratory in California, demonstrating the system's effectiveness in eliminating 99.998% of Influenza A. The virus is the primary cause of seasonal flu, projected to affect 6,400,000 – 11,000,000 Americans in 2021-2022. Flu is considered a major epidemic linked to a wide array of illnesses that may affect school attendance, worker absenteeism, and daily productivity.
In order to simulate real-life indoor spaces, testing took place in a sealed 10'x8'x8' chamber, which is around half the size of a classroom. According to the results, Aura Air devices successfully removed 99.998% of Influenza A within 60 minutes, with a significant impact of 63.69% in the first 15 minutes and 79.4% after 30 minutes.
Aura Air supplied a smart air device designed to be mounted on the ceiling or wall in a room to decrease the concentration of pathogens and particulates in the air of an occupied space. This study evaluated the Aura Air unit's effectiveness in its ability to reduce aerosolized Influenza A.
The test was conducted in a 10'x8'x8' chamber following BSL-3 standards. The temperature during testing was approximately 68 ±2F, with a relative humidity of 30%. A 2.47 x 107 CEID50/mL concentration of Influenza A viral suspension media was nebulized into the room with mixing fans before collection. Air sample collections occurred at 0, 15, 30, and 60 minutes of device operation.
The experiment displayed an accelerated reduction in viral concentration than the natural viability loss observed in the controls. After 30 minutes of operation, 5.17 x 106 CEID50/mL of active Influenza A was recovered in the air. The device reduced active Influenza A concentrations to 4.80 x 102 CEID50/mL after 60 minutes.
The results were plotted to show the amount of active Influenza A collected with and without the Aura Air operating for 60 minutes. The control displayed a gradual viability loss over time, while the Aura Air displayed a more rapid reduction. Against aerosolized Influenza A, an initial concentration of 2.47 x 107 CEID50/mL decreased to 8.95 x 106 CEID50/mL after 15 minutes of exposure. More prolonged exposure resulted in a more significant reduction in collectible, active Influenza A virus, as shown by the 5.17 x 106 CEID50/mL collected at 30 minutes and 4.80 x 102 CEID50/mL after 60 minutes.
The wall-mounted Aura Air device demonstrated a significant reduction of aerosolized Influenza A virus in a controlled environment. At 15 minutes of operation, a 63.69% gross reduction of active Influenza A was observed and a 99.998% gross reduction after 60 minutes of operation.
When aerosolizing pathogens and collecting said pathogens, some variables cannot be fully accounted for, namely, placement of pathogen, collection volume, collection points, drop rate, surface saturation, virus destruction on collection, virus destruction on aerosolization, and possibly others. Every effort was made to address these constraints with the design and execution of the trials. And these efforts are reflected in the meaningful recovery of virus in the control test.
Considering the variables, the Aura Air device achieved a measurable amount of reduction at each time point (T-15, T-30, and T-60), demonstrating the device efficiently reduced Influenza A from the air samples collected under controlled conditions.